Bile reflux

Summary

Bile reflux (MONDO:0006677) is a disease and 7 clinical trials. Top therapeutic interventions include esomeprazole. A subtype of biliary tract disorder — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 7

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	bile reflux
Mondo ID	MONDO:0006677
EFO	EFO:1000838
MeSH	D001655
DOID	DOID:12237
UMLS	C0005403
MedGen	2243
Is cancer (heuristic)	no

Disease family

This is a subtype of biliary tract disorder. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › digestive system disorder › hepatobiliary disorder › biliary tract disorder › bile reflux

Related subtypes (14): bile duct disorder, biliary tract neoplasm, gallstones, primary biliary cholangitis, postcholecystectomy syndrome, Alagille syndrome, isolated agenesis of gallbladder, cholelithiasis, ketamine-induced biliary dilatation, follicular cholangitis and pancreatitis, idiopathic ductopenia, Caroli syndrome, isolated congenital hepatic fibrosis, Rokitansky-Aschoff sinuses of the gallbladder

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 7.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	7

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00441831	Not specified	UNKNOWN	The Revolutions of Helicobacter Pylori Infection, Bacterial Density, and Histological Features After Antrectomy
NCT02685150	Not specified	COMPLETED	Endoscopic Tri-Modal Imaging to Distinguish Functional Dyspepsia From Reflux Disease
NCT03097887	Not specified	UNKNOWN	Omega Loop Gastric Bypass With And Without Anti-Reflux Sutures
NCT04660058	Not specified	COMPLETED	Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric Cancer
NCT04845438	Not specified	UNKNOWN	Evaluation of Biliary Reflux After Mini-gastric Bypass With Using the Biliary Reflux Index
NCT05131802	Not specified	COMPLETED	Bile Reflux Gastropathy: Prevalence and Risk Factors After Therapeutic Biliary Interventions
NCT05369572	Not specified	UNKNOWN	Connection Between Tongue Signs and Bile Reflux Analysed With Artificial Intelligence

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
ESOMEPRAZOLE	4	1